HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥First-Line (1L) Olomorasib + Chemoimmunotherapy (Chemo-IO) in KRAS G12C-Mutant NSCLC: Updated Results From the LOXO-RAS-20001 and SUNRAY-01 Trials 🎙️ @mvnegrao 🔢2652RO 🎯ORR 61%, DCR 88%, Median DOR 14.5mo, Median PFS 11.8mo (n=77; 18.7-Mo Follow-Up); Efficacy Across PD-L1 Levels Incl. <1% (ORR 50%); No New Safety Signals ☑️NCT04956640 🔗 https://t.co/p4tFUd6NwV @OncoAlert @Larvol @myESMO @IASLC @KRASKickers
热度 1 · 0 赞 · 0 回复 · 1 转发
会议摘要
NCT04956640NCT04956640按 - **标题 / Title：** Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) 对上
- **标题 / Title：** Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)读摘要原文 →来源：HHorinouchi · x.com